- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00566202
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
1. august 2014 oppdatert av: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Phase IIa Multicenter, Randomized, Double-blind, Double-dummy, and Placebo- and Active Controlled Study to Investigate the Safety and Efficacy of JNJ-18038683 Administered to Subjects With Major Depressive Disorder
The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study is being done to assess safety and tolerability and to explore the effectiveness of a new, experimental drug in the treatment of moderate to severe depression.
Approximately 225 patients with depression will be recruited for the study.
Patients who meet study criteria will need to stop taking any depression medications they are currently using.
They will be randomly assigned to one of 3 treatment arms; each patient has an equal chance of receiving 20 mg JNJ-18038683, 20 mg escitalopram, or placebo.
Placebo has no active drug.
Escitalopram is a drug currently approved to treat depression.
This is a blinded study, ie the patient, the study doctor, and the study sponsor will not know what treatment the patient receives until all patients complete the study.
Patients receiving either escitalopram or JNJ-18038683 will be titrated up to their assigned dose, receiving 10 mg doses for one week prior to increasing to 20 mg.
Patients who are not able to tolerate 20 mg of JNJ-18038683 will be allowed to drop down to the 10 mg dose at any time after the titration period.
Patients taking 20 mg escitalopram will receive 10 mg at their final week to taper off of the drug.
Patients will receive a drug blister card at each weekly visit containing drug for the upcoming week.
The study doctor and the sponsor will monitor the study for the occurrence of possible side effects.
In addition to a screening visit, patients will return weekly for 9 additional study visits.
After completing the study, patients may resume other depression medications.
Medical and psychiatric history, physical examination, blood pressure, heart rate, temperature, weight and electrocardiograms (ECGs) will be checked periodically.
Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level.
Questionnaires relating to depression, sleep and sexual experience will be administered throughout the study.
Each day for nine weeks, patients will take orally two JNJ-18038683 tablets, active and/or placebo, and two escitalopram capsules, active and/or placebo.
Studietype
Intervensjonell
Registrering (Faktiske)
67
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater
-
-
California
-
Beverly Hills, California, Forente stater
-
Glendale, California, Forente stater
-
San Diego, California, Forente stater
-
-
Florida
-
Bradenton, Florida, Forente stater
-
Maitland, Florida, Forente stater
-
Orlando, Florida, Forente stater
-
-
Georgia
-
Atlanta, Georgia, Forente stater
-
-
Idaho
-
Eagle, Idaho, Forente stater
-
-
Illinois
-
Chicago, Illinois, Forente stater
-
-
Kansas
-
Prairie Village, Kansas, Forente stater
-
Topeka, Kansas, Forente stater
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater
-
Shreveport, Louisiana, Forente stater
-
-
New Jersey
-
Nutley, New Jersey, Forente stater
-
-
New York
-
Brooklyn, New York, Forente stater
-
Cedarhurst, New York, Forente stater
-
Fresh Meadows, New York, Forente stater
-
-
Ohio
-
Cincinnati, Ohio, Forente stater
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater
-
-
Oregon
-
Portland, Oregon, Forente stater
-
-
Pennsylvania
-
Norristown, Pennsylvania, Forente stater
-
-
Tennessee
-
Memphis, Tennessee, Forente stater
-
-
Texas
-
Austin, Texas, Forente stater
-
Irving, Texas, Forente stater
-
-
Virginia
-
Richmond, Virginia, Forente stater
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 60 år (Voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Diagnosed with moderate to severe major depressive disorder
- Willing to use acceptable methods of birth control throughout the study and for 3 months after
- In good general health
Exclusion Criteria:
- No history or current diagnosis of other psychiatric conditions such as bipolar disorder, psychotic disorder, general anxiety disorder, anorexia, obsessive compulsive disorder, post traumatic stress disorder, antisocial personality disorder, mental retardation, pervasive developmental disorder, or cognitive disorder
- No history or presence of drug abuse
- No use of prescription medications or herbal medications other than hormone replacement therapies
- No prior history of heart disease or current significant blood, lung, kidney, liver, heart, breathing, neurologic or thyroid disorders
- No patients who are either pregnant or nursing
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Form= capsule, route= oral use.
Administration once daily for 8 weeks.
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use.
Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
|
|
Aktiv komparator: Escitalopram
|
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use.
Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
|
|
Eksperimentell: JNJ-18038683
|
Form= capsule, route= oral use.
Administration once daily for 8 weeks.
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use.
Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Explore the effectiveness of JNJ-18038683 in patients with moderate to severe depression as determined by accepted clinical assessments done throughout the study.
Tidsramme: Clinical assessments to evaluate depression will be done 8 times at weekly visits from baseline through the Week 7 visit.
|
Clinical assessments to evaluate depression will be done 8 times at weekly visits from baseline through the Week 7 visit.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Explore the safety and tolerability of JNJ-18038683 in patients with moderate to severe depression by assessing adverse events, vital signs, laboratory test results, ECGs and physical exams.
Tidsramme: Vital signs will be collected weekly throughout the study; ECGs will be collected at screening, baseline, Wks 3 and 7; Laboratory test will be collected at screening, baseline, and Wks 1,3,5,7 and 8. Adverse Events will be throughout the study.
|
Vital signs will be collected weekly throughout the study; ECGs will be collected at screening, baseline, Wks 3 and 7; Laboratory test will be collected at screening, baseline, and Wks 1,3,5,7 and 8. Adverse Events will be throughout the study.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Studieleder: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. desember 2007
Primær fullføring (Faktiske)
1. desember 2008
Studiet fullført (Faktiske)
1. desember 2008
Datoer for studieregistrering
Først innsendt
29. november 2007
Først innsendt som oppfylte QC-kriteriene
29. november 2007
Først lagt ut (Anslag)
3. desember 2007
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
6. august 2014
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. august 2014
Sist bekreftet
1. august 2014
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Atferdssymptomer
- Psykiske lidelser
- Stemningsforstyrrelser
- Depresjon
- Depressiv lidelse
- Depressiv lidelse, major
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Psykotropiske stoffer
- Serotoninopptakshemmere
- Nevrotransmitter opptakshemmere
- Membrantransportmodulatorer
- Serotoninmidler
- Antidepressive midler
- Antidepressive midler, andre generasjon
- Citalopram
Andre studie-ID-numre
- CR014617
- C-2007-007 (Annen identifikator: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .